Moral, John Alec
Leung, Joanne
Rojas, Luis A.
Ruan, Jennifer
Zhao, Julia
Sethna, Zachary
Ramnarain, Anita
Gasmi, Billel
Gururajan, Murali
Redmond, David
Askan, Gokce
Bhanot, Umesh
Elyada, Ela
Park, Youngkyu
Tuveson, David A.
Gönen, Mithat
Leach, Steven D.
Wolchok, Jedd D.
DeMatteo, Ronald P.
Merghoub, Taha
Balachandran, Vinod P.
Article History
Received: 26 March 2019
Accepted: 31 December 2019
First Online: 19 February 2020
Competing interests
: V.P.B. is a recipient of an immuno-oncology translational research grant from Bristol-Myers Squibb and is an inventor on a patent application related to work on neoantigen modelling. S.D.L. is a member of the scientific advisory board of Nybo Pharmaceuticals, and co-founder of Episteme Prognostics. J.D.W. is a consultant for Adaptive Biotech, Advaxis, Amgen, Apricity, Array BioPharma, Ascentage Pharma, Astellas, Bayer, Beigene, Bristol-Myers Squibb, Celgene, Chugai, Elucida, Eli Lilly, F Star, Genentech, Imvaq, Janssen, Kleo Pharma, Linneaus, MedImmune, Merck, Neon Therapuetics, Ono, Polaris Pharma, Polynoma, Psioxus, Puretech, Recepta, Trieza, Sellas Life Sciences, Serametrix, Surface Oncology and Syndax; is a recipient of research support from Bristol-Myers Squibb, Medimmune, Merck Pharmaceuticals and Genentech; has equity in Potenza Therapeutics, Tizona Pharmaceuticals, Adaptive Biotechnologies, Elucida, Imvaq, Beigene, Trieza and Linneaus; and has received an honorarium from Esanex. T.M. is a consultant for Immunos Therapeutics and Pfizer; is a co-founder with equity in Imvaq Therapeutics; receives research funding from Bristol-Myers Squibb, Surface Oncology, Kyn Therapeutics, Infinity Pharmaceuticals Inc., Peregrine Pharmaceuticals Inc., Adaptive Biotechnologies, Leap Therapeutics Inc. and Aprea; and is an inventor on patent applications related to work on Oncolytic Viral Therapy, Alpha Virus Based Vaccine, Neo Antigen Modeling, CD40, GITR, OX40, PD-1 and CTLA-4. M. Gururajan is an employee of Bristol-Myers Squibb and has financial interest in the company.